Arcus Biosciences, Inc. (RCUS) Stock Price & Analysis
Arcus Biosciences, Inc. (RCUS) fell 1.56% to USD 29.66 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
RCUS last closed at USD 30.13; the session ranged USD 29.42–30.07 on volume of 736,980 shares. Market capitalization is $3.73B, with a 52-week range of USD 11.1–31.74 (NYQ). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 29.66 |
|---|---|
| Change | ▼ 1.56% (down) |
| Previous Close | USD 30.13 |
| Open | USD 29.64 |
| Day Range | USD 29.42 – 30.07 |
| 52-Week Range | USD 11.1 – 31.74 |
| Volume | 736,980 shares |
| Market Cap | $3.73B |
| Exchange | NYQ |
Technical Analysis (RCUS)
Nexqual's technical model rates RCUS "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.24 (neutral) |
| vs SMA50 | Above (USD 29.19) |
| MACD | 0.36 (positive) |
Analyst Ratings (RCUS)
Wall Street analysts rate RCUS "None" based on 12 analysts, with a mean price target of USD 38.33 (range USD 23–47), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 38.33 |
| High Target | USD 47 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 10 / 3 / 0 |
Earnings (RCUS)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD -0.88 |
| Revenue Estimate | $12.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.72 vs est -0.81 ▲ beat |
| 2026-03-31 | USD -1.02 vs est -0.83 ▼ miss |
| 2025-12-31 | USD -0.89 vs est -1.08 ▲ beat |
| 2025-09-30 | USD -1.27 vs est -1.29 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (RCUS)
| Total Revenue | $117.00M |
|---|---|
| Revenue Growth (YoY) | -74.40% |
| Gross Margin | +0.00% |
| Operating Margin | -234.15% |
| Profit Margin | +0.00% |
| ROE | -90.82% |
| Debt / Equity | 51.29 |
| Current Ratio | 3.82 |
| Total Cash | $702.00M |
| Total Debt | $238.00M |
| Free Cash Flow | $-270.62M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (RCUS)
Nexqual rates Arcus Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $702M cash vs $238M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$271M, burning cash |
| Efficiency | Critical — ROE -91%, ROA -30.4% |
Ownership (RCUS)
| Insider Ownership | +28.80% |
|---|---|
| Institutional Ownership | +74.91% |
| Shares Outstanding | 125.77M |
| Float | 90.53M |
| Short % of Float | +17.75% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (RCUS)
Arcus Biosciences, Inc. is led by Terry J. Rosen (age 65), Co-Founder, Chairman & CEO, per Nexqual as of September 8, 2026 at 05:44 UTC.
| Co-Founder, Chairman & CEO | Terry J. Rosen (age 65) |
|---|---|
| Co- Founder & President | Juan Carlos Jaen (age 67) |
| Principal Financial Officer & CFO | Robert C. Goeltz (age 52) |
| Chief Scientific Officer | Jonathan Yingling (age 56) |
| Vice President of Investor Relations & Strategy | Pia Eaves |
Major Backers & Investors (RCUS)
Notable institutional backers of Arcus Biosciences, Inc. include Gilead Sciences Inc, Wellington Management, Montanova Capital LLC, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gilead Sciences Inc | 24.68% |
| Wellington Management | 4.63% |
| Montanova Capital LLC | 3.75% |
| FMR, LLC | 3.18% |
| Citadel | 2.46% |
| Woodline Partners LP | 2.36% |
| Fidelity | 2.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.84% |
| Vanguard Group | 13.05% |
| State Street | 6.77% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Arcus Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
- The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
- It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
- In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.56 | ▼ 1.06% |
| ARVN | Arvinas, Inc. | USD 9.39 | ▼ 2.09% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| IDYA | IDEAYA Biosciences, Inc. | USD 39.86 | ▼ 0.77% |
| XNCR | Xencor, Inc. | USD 26.61 | ▼ 1.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.